425: ACELYRIN and Alumis Amend Merger Agreement, Boosting ACELYRIN Stockholder Ownership

ACELYRIN and Alumis have amended their merger agreement, increasing ACELYRIN stockholders' ownership in the combined company to approximately 48% on a fully diluted basis.

Summary

• ACELYRIN and Alumis have amended their merger agreement, increasing ACELYRIN stockholders' ownership in the combined company.
• Under the amended terms, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock.
• This results in Alumis stockholders owning approximately 52% and ACELYRIN stockholders owning approximately 48% of the combined company on a fully diluted basis.
• The merger aims to create a leading clinical-stage immunology company with a diversified portfolio.
• The combined company is expected to have approximately $737 million in pro forma cash as of December 31, 2024, providing runway into 2027.
• The special meeting of stockholders for both companies is scheduled for May 19, 2025.
• The transaction is expected to close in the second quarter of 2025, pending stockholder approval and customary closing conditions.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook on the merger, highlighting increased stockholder ownership and extended cash runway, but acknowledges risks and past setbacks.

Positives

• Increased ownership for ACELYRIN stockholders in the combined company.
• Creation of a leading clinical-stage immunology company with a diversified pipeline.
• Extended cash runway into 2027 for the combined company.
• Potential for value creation through synergies and scale.
• The ACELYRIN board believes that the combination with Alumis will be significantly value accretive to ACELYRIN stockholders as a result of synergies and scale to be achieved through the proposed merger as well as reduced execution risk versus a standalone path as a single asset company.

Negatives

• ACELYRIN's standalone value was perceived by the market as less than its cash value prior to the merger announcement.
• ACELYRIN has faced clinical setbacks and management departures that have impacted growth prospects.
• There is a risk that the anticipated benefits and synergies of the proposed transaction may not be fully realized or may take longer to realize than expected.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Required approvals may not be received.
• The announcement, pendency, or completion of the transaction may negatively impact Alumis' or ACELYRIN's ability to attract and retain key personnel.
• The transaction may divert management's attention from ongoing business operations.
• Legal proceedings related to the transaction could arise.
• Anticipated benefits and synergies may not be fully realized or may take longer to realize than expected.
• Integration of the two companies post-closing may not occur as anticipated.
• There are risks relating to the value of Alumis securities to be issued in the proposed transaction.

Future Outlook

The combined company expects to advance its pipeline through multiple key data readouts and fund operating expenses into 2027.

Management Comments

• Martin Babler, President, Chief Executive Officer and Chairman of Alumis, stated that the revised terms enable enhanced value creation opportunities.
• Bruce Cozadd, Chair of the ACELYRIN Board of Directors, mentioned that the amended agreement reflects dialogue with stockholders and builds upon the previously announced agreement.

Industry Context

The merger reflects a trend of consolidation in the biotech industry, particularly among companies focused on immunology, to diversify pipelines and extend cash runways.

Comparison to Industry Standards

• Viridian Therapeutics, another company focused on Thyroid Eye Disease (TED), has a lead asset, Veligrotug, with Phase 3 topline data and BLA submission expected in the second half of 2025.
• The combined company's management team has experience similar to that of Viela Bio, with Alumis' Chief Medical Officer being the CMO and co-founder of Viela Bio.
• Alumis' Chief Commercial Officer ran the TEPEZZA franchise at Amgen/Horizon, indicating expertise in the ophthalmology space.
• The document compares ACELYRIN's situation to other biotechs trading below cash value, such as Pliant and BBC.

Stakeholder Impact

• ACELYRIN stockholders will receive increased ownership in the combined company.
• The merger is expected to create a stronger combined company, potentially benefiting both Alumis and ACELYRIN stockholders.
• The combined company is expected to have a longer cash runway, providing more stability for employees.
• The merger could lead to synergies and cost savings, potentially impacting employees.

Next Steps

• File supplemental proxy materials with the SEC.
• Hold Special Meetings of Stockholders for both companies on May 19, 2025.
• Obtain stockholder approval for the transaction.
• Satisfy other customary closing conditions.
• Close the transaction during the second quarter of 2025.

Key Dates

Keywords

merger, ACELYRIN, Alumis, immunology, stockholders, ownership, clinical-stage, pipeline, cash runway, ESK-001, Lonigutamab